share_log
Reuters ·  Oct 15 20:00
Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of Vtx002 (Tamuzimod) in Ulcerative Colitis at Ueg Week 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment